Cognitive Effects of Immunomodulatory Drugs in MS

Comparison of the Cognitive Effects of Three Immunomodulatory Drugs in Relapsing-Remitting Multiple Sclerosis: A Longitudinal Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00229502

Enrollment

Registered

2005-09-29

Start date

2005-09-30

Completion date

2011-12-31

Last updated

2012-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Copaxone, or Rebif).

Detailed description

In addition this study will compare the patients' personal view of how they are doing, any changes in physical disability, and the frequency and severity of relapses over the three year period.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Diagnosis of RRMS for at least one year, * Currently on one of three immunomodulatory drugs (Avonex, Copaxone, or Rebif), * Visual Acuity is 20/50 or better, * patient has four color vision, * Must have at least a high school education

Exclusion criteria

* History of head injury, drug/alcohol abuse, and/or psychiatric problems, -current diagnosis of a severe or lifethreatening disease other than MS, * currently taking immunosuppressant medication, * resides greater than 200 miles from the study site

Countries

United States

Outcome results